Phase 3 – Regenerative Medicine

Phase III, launching in Q1 of 2018, will begin with acquisition/development of Regenerative Medicine protocols and patented technologies. With the Companies experience in the Stem Cell and Regenerative Medicine sectors, we feel confident that we have identified the best market opportunity utilizing innovative published scientific data to separate BioStem Technologies from its competitors.